Results 31 to 40 of about 7,548 (263)

Retrospective trial of long acting analogues detemir and degludec usage in children and adolescents to overcome glucose variability caused by dawn phenomenon and reverse dawn phenomenon

Сахарный диабет, 2021
Backgraund: Children with type 1 diabetes mellitus (T1DM) need more insulin late in the evening (reverse dawn phenomenon (RDP)), and adolescents need more insulin yearly in the morning (dawn phenomenon (DP)); these cause blood glucose variability. Modern
A. V. Vitebskaya, E. V. Shreder, A. V. Popovich, E. A. Pisareva   +3 more
doaj   +1 more source

A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia [PDF]

, 2016
Aims: A prospective meta-analysis of phase 3 trials showed lower rates of nocturnal hypoglycaemia with insulin degludec vs. insulin glargine. We investigated the consistency of the results across different definitions of hypoglycaemia.
Bode, Brod, Brod, Evans, Evans, Evans, Garber, Gough, Heise, Heise, Heller, Hollander, Landstedt-Hallin, Mathieu, Meneghini, Onishi, Ratner, Rodbard, Seaquist, Wright, Zinman   +20 more
core   +1 more source

Insulin degludec overdose in an adolescent with type 1 diabetes: proactive management including monitoring using the Freestyle Libre flash glucose monitoring system

Endocrinology, Diabetes & Metabolism Case Reports, 2018
An adolescent with type 1 diabetes and a history of self-harm, which included intentional overdoses and insulin omission, presented with an insulin degludec overdose.
Harmony Thompson, Helen Lunt, Cate Fleckney, Steven Soule   +3 more
doaj   +1 more source

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study [PDF]

, 2013
Aims/hypothesis: Insulin degludec (Des(B30)LysB29(γ-Glu Nε-hexadecandioyl) human insulin; IDeg) is a new basal insulin with an ultra-long flat action profile.
AE Gold, AJ Garber, B Raju, B Zinman, BM Frier, CG Fanelli, CR Bowie, D Wechsler, F Smeeton, I Jonassen, IJ Deary, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, KI Birkeland, O Tschritter, P Galassetti, P Rossetti, PA Goldberg, RE Ratner, RE Ratner, RJ McCrimmon, RM Reitan, RT Wilkinson, S Dagogo-Jack, S Heller, S Heller, SCL Gough, SN Davis, T Heise, UK Hypoglycaemia Study Group, V McAulay, World Medical Association   +30 more
core   +2 more sources

Characterisation of insulin analogues therapeutically available to patients [PDF]

, 2018
The structure and function of clinical dosage insulin and its analogues were assessed. This included ‘native insulins’ (human recombinant, bovine, porcine), ‘fast-acting analogues’ (aspart, glulisine, lispro) and ‘slow-acting analogues’ (glargine ...
Adams, Gary G., Alzahrani, Qushmua E., Ballance, Simon, Besong, David T.M., Chayen, Naomi, Gillis, Richard B., Harding, Stephen E., Jiwani, Shahwar I., Kok, M. Samil, Lithgo, Ryan, Meal, Andrew, Morgan, Paul S., Zobel, Hanne   +12 more
core   +5 more sources

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?

Clinical Medicine Insights: Endocrinology and Diabetes, 2012
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a ...
Sami N. Nasrallah, L. Raymond Reynolds
doaj   +1 more source

Clinical use of the co-formulation of insulin degludec and insulin aspart [PDF]

, 2016
AimsTo provide a review of the available data and practical use of insulin degludec with insulin aspart (IDegAsp). Premixed insulins provide basal and prandial glucose control; however, they have an intermediate-acting prandial insulin component and do ...
A., A., A., A. G., G., G. R., J., J. S., K., Kumar, L., M., M., P. D., R., R., S., S. C., T., T.   +19 more
core   +1 more source

IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting [PDF]

, 2017
Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please ...
Barnaby Hunt, Jakob Langer, Michelle Mocarski, William J. Valentine   +3 more
core   +2 more sources

Insulin degludec is a new ultra-long-acting insulin analogue

Сахарный диабет, 2014
Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment.
Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova   +1 more
doaj   +1 more source

The use of long-acting insulin degludec in adult patients with type 2 diabetes mellitus in real clinical practice in Russia

Сахарный диабет, 2023
BACKGROUND: Effective glycaemic control remains the most important task in managing the risks of Diabetes type 2 complications development. In this regard, the choice of insulin preparations with minimal variability of action is of utmost importance ...
G. R. Galstyan
doaj   +1 more source